Exhibit 10.1
EXCHANGE AGREEMENT
This Exchange Agreement (this “Agreement”) is dated as of November 13, 2026, among SPAR Group, Inc., a Delaware corporation (the “Company”); SPAR Marketing Force Inc., a Nevada corporation and wholly owned subsidiary of the Company (“SPM”); ReposiTrak, Inc., a Nevada corporation (“TRAK”); and PC Group, Inc., a Utah corporation and wholly owned subsidiary of TRAK (“PCG”). TRAK, PCG and any affiliate thereof shall hereinafter be referred to as a “TRAK Party”.
RECITALS
A. The Company owes PCG (the “Noteholder”) principal and accrued interest under the Amended and Restated Senior Unsecured Promissory Note held by the Noteholder in the amount of approximately $4.0 million as of the date of this Agreement (the “Note”);
B. TRAK and PCG also beneficially own 8,900,406 shares of the Company’s common stock, par value $0.01 per share (“Common Stock”) (the “Existing Shares”);
C. TRAK and PCG have offered to cancel and terminate all Outstanding Indebtedness (as defined in Section 1.1) under the terms of the Note (i) in exchange for (A) shares of a new series of preferred stock of the Company, Series C Convertible Preferred Stock, $0.01 par value (“Series C Preferred”) (the “Note Exchange”), and (B) the Warrant (as defined in Section 3); and (C) exchange all Existing Shares for Series C Preferred and the Warrant (“Common Exchange” and together with the Note Exchange, the “Exchanges”), each under the terms and conditions set forth below in this Agreement;
D. In connection with the Note Exchange and Common Exchange, TRAK has agreed to provide a $1.5 million credit facility to the Company on the terms and conditions set forth in Exhibit A to this Agreement (“Credit Agreement”); and
E. As of the date of this Agreement, the Company owes TRAK approximately $1,105,800, separate from and in addition to the Outstanding Indebtedness under the Note (together with all interest, fees and other amounts accrued or accruing thereon, the “Existing TRAK Obligations”), which the parties intend to remain outstanding and payable in full, unaffected by this Agreement and the transactions contemplated thereby; and
F. The Parties desire to consummate the Note Exchange and the Common Exchange, and enter into such other agreements, each on the terms and conditions set forth in this Agreement.
AGREEMENT
For good and valuable consideration, the parties hereto agree as follows:
1. The Exchanges
1.1 Note Exchange. At the Closing, the Noteholder will surrender the Note and all principal and accrued and unpaid interest owed under it as of the Closing Date (the “Outstanding Indebtedness”). In exchange, the Company will issue to the Noteholder a number of shares of Series C Preferred equal to the Outstanding Indebtedness divided by the Stated Value, as defined below. On that issuance, the Note shall be paid in full and cancelled, and neither the Company nor SPM shall have any further obligation to PCG under the terms of the Note. The parties expect the Outstanding Indebtedness to be approximately $4,000,000 on the Closing Date, with the exact amount to be confirmed in writing by the parties before the Closing.
1.2 Common Exchange. At the Closing, TRAK and PCG will sell, assign and transfer to the Company all Existing Shares in exchange for the issuance by the Company to TRAK (or as TRAK directs between itself and PCG) a number of shares of Series C Preferred with an aggregate Stated Value equal to $3,359,605 (subject to Section 1.4). Upon issuance of the Series C Preferred to TRAK, the Existing Shares will be cancelled.
1.3** ** Future Obligations**.** After the Closing, TRAK may, from time to time by written notice to the Company, exchange all or part of any amounts the Company or SPM then owes TRAK (“Future Obligations”) for shares of Series C Preferred having an aggregate Stated Value equal to the amount of the Future Obligations so exchanged, subject to Section 1.4. The Company will issue the additional shares of Series C Preferred issuable in exchange for Future Obligations within five (5) business days after the notice, and the exchanged amount will then be paid in full.
1.4* * Fractional Shares. Series C Preferred shall not be issued in fractions of a share. Any fraction of a share of Series C Preferred that would otherwise be issuable under this Agreement shall be rounded up to the next whole share, consistent with the Certificate of Designations.
1.5 Anti-Dilution. For so long as TRAK or any of its affiliates holds any Series C Preferred, the following shall apply:
1.5.1 Issuance of Additional Shares. If the Company issues or sells any shares of Common Stock or any rights, options, warrants or other securities directly or indirectly convertible into or exercisable or exchangeable for Common Stock (“Convertible Securities”) (each, a “Dilutive Issuance”), then within five (5) business days after the Dilutive Issuance the Company shall issue to TRAK (or to such of its affiliates as TRAK directs), without further consideration, a number of additional shares of Series C Preferred (the “Anti-Dilution Shares”) such that the TRAK Percentage immediately after the Dilutive Issuance and the issuance of the Anti-Dilution Shares equals the TRAK Percentage immediately before the Dilutive Issuance. Each of the following shall constitute a Dilutive Issuance, notwithstanding that the securities are issued to TRAK or any of its affiliates: (A) any issuance of Series C Preferred under the Credit Agreement, whether on conversion of amounts outstanding under the Credit Agreement, as consideration for any Sourced Financing (as defined in the Credit Agreement) or otherwise; (B) any issuance of Common Stock on exercise of the Warrant or of any warrant issued under the Credit Agreement; and (C) any issuance of Series C Preferred as dividends or for Future Obligations.
1.5.2 Calculation. The number of Anti-Dilution Shares to be issued for each Dilutive Issuance shall equal (P × N × CP) ÷ ((1 − P) × SV), where “P” is the TRAK Percentage immediately before the Dilutive Issuance (expressed as a decimal); “N” is the number of shares of Common Stock issued in the Dilutive Issuance, together with the maximum number of shares of Common Stock issuable on conversion, exercise or exchange of any Convertible Securities issued in the Dilutive Issuance; “CP” is the Conversion Price then in effect; and “SV” is the Stated Value.
1.5.3 Definitions. “TRAK Percentage” means, at any time, a fraction, expressed as a percentage, (i) the numerator of which is the sum of all shares of Common Stock then held by TRAK and its affiliates and all Conversion Shares issuable on conversion of all Series C Preferred then held by TRAK and its affiliates, and (ii) the denominator of which is the sum of all shares of Common Stock then outstanding, all Conversion Shares issuable on conversion of all Series C Preferred then outstanding, and the maximum number of shares of Common Stock issuable on conversion, exercise or exchange of all Convertible Securities issued in prior Dilutive Issuances and then outstanding. The TRAK Percentage shall be calculated without regard to the beneficial ownership limitation in Section 2.3, the Voting Cap or any other limitation on conversion or voting. “Credit Agreement” means the Revolving Credit Agreement between the Company and TRAK described in Recital D and Exhibit A, as amended from time to time.
1.5.4 Excluded Issuances. The Parties agree and acknowledge that, notwithstanding anything to the contrary herein, the issuance of Common Stock upon conversion of Series C Preferred and the issuance of Anti-Dilution Shares shall each constitute a Dilutive Issuance for purposes of this Section 1.5. No issuance of equity securities to TRAK or its affiliates shall be excluded solely because TRAK or such affiliate is the recipient of such securities.
1.5.5 Notice, Terms. The Company shall give TRAK written notice of each Dilutive Issuance within two (2) business days after it occurs, setting out in reasonable detail the securities issued and the Company’s calculation of the Anti-Dilution Shares. Each Anti-Dilution Share shall have the same Stated Value, rights, preferences and privileges as each other share of Series C Preferred.
1.5.6 Authorized Shares. The Company shall at all times keep designated under the Certificate of Designations, and authorized and reserved, a sufficient number of shares of Series C Preferred and Common Stock to permit the issuance of all Anti-Dilution Shares and the conversion of all Anti-Dilution Shares into Common Stock, and shall take all corporate action necessary to do so; provided that, until the amendment described in Section 8.5 becomes effective, the Company’s obligations under this Section 1.5.6 as to Common Stock shall be satisfied by compliance with Section 2.8.
1.6 Existing TRAK Obligations. Nothing in this Agreement, the Certificate of Designations, the Warrant, the Credit Agreement or any transaction contemplated by any of them shall forgive, release, discharge, reduce, convert, exchange, subordinate or otherwise impair the Existing TRAK Obligations, all of which shall remain outstanding and payable in full in accordance with their terms; provided that TRAK may, in its sole discretion, elect to exchange all or any part of the Existing TRAK Obligations for Series C Preferred under Section 1.3. The Existing TRAK Obligations are not part of the Outstanding Indebtedness and shall not be surrendered or cancelled at the Closing. The Company acknowledges that the Existing TRAK Obligations are valid and owing and are not subject to any defense, offset or counterclaim.
1.7 Ownership Cap. Notwithstanding anything to the contrary in this Agreement, the Certificate of Designations, the Warrant, the Credit Agreement, any warrant issued under the Credit Agreement or any other agreement or instrument relating to any of them (collectively, the “Transaction Documents”), in no event shall (a) the Common Percentage exceed 50% at any time, or (b) the TRAK Parties cast, or have counted, more than 50% of the votes cast and counted on any matter, which shall be limited as provided in the Voting Cap (together, the “Ownership Cap”). Notwithstanding the foregoing, the Ownership Cap, this Section 1.7, Section 2.3, the Voting Cap and every other limitation in any Transaction Document on the Common Percentage, on the beneficial ownership of Common Stock by the TRAK Parties or on the votes that the TRAK Parties may cast shall terminate and cease to apply on December 23, 2027 (the “Sunset Date”). On and after the Sunset Date, the TRAK Parties may convert, exercise, exchange and acquire securities of the Company, and vote all of them, without regard to any such limitation, even if as a result the TRAK Parties hold more than 50% of the outstanding Common Stock or of the voting power of the Company. The termination of this Section 1.7 does not validate any issuance, transfer or acquisition that violated it before the Sunset Date.
1.7.1 Definitions. “TRAK Parties” means TRAK, PCG, each of their affiliates, and each other person whose beneficial ownership of Common Stock would be aggregated with that of TRAK or PCG for purposes of Section 13(d) of the Exchange Act, including as a member of a “group.” “Common Percentage” means, at any time, a fraction, expressed as a percentage, (i) the numerator of which is the number of shares of Common Stock then held of record or beneficially owned (within the meaning of Rule 13d-3 under the Exchange Act) by the TRAK Parties, excluding Common Stock issuable on conversion of Series C Preferred or on exercise of the Warrant or any other warrant, option or right until it is issued, and (ii) the denominator of which is the number of shares of Common Stock then outstanding.
1.7.2 Limitation on Conversions, Exercises and Acquisitions. The Company shall not issue or transfer any Common Stock to any TRAK Party, and TRAK shall not, and shall cause each other TRAK Party not to, acquire any Common Stock (whether from the Company or any other person, and whether by conversion, exercise, purchase, exchange or otherwise), to the extent that, immediately after giving effect to the issuance or acquisition, the Common Percentage would exceed 50%. Without limiting the foregoing, this Section 1.7.2 applies to (a) any conversion of Series C Preferred; (b) any exercise of the Warrant or of any warrant issued under the Credit Agreement; (c) any other issuance of Common Stock under any Transaction Document; and (d) any purchase or other acquisition of Common Stock by a TRAK Party from any other person.
1.7.3 Effect of Limitation. To the extent a conversion or exercise is limited by Section 1.7.2, (a) the Series C Preferred, the Warrant or the other warrant, as applicable, shall remain outstanding and convertible or exercisable in accordance with its terms, subject to this Section 1.7; (b) no exercise price shall be payable for any shares not issued; and (c) any fractional share of Common Stock that would otherwise be rounded up shall instead be rounded down if rounding up would cause the Common Percentage to exceed 50%.
1.7.4 Company Actions; Excess Shares. The Company shall not redeem, repurchase or otherwise acquire any shares of Common Stock, or take any other action, if immediately after giving effect to it the Common Percentage would exceed 50%. If, notwithstanding this Section 1.7, the Common Percentage exceeds 50% at any time for any reason, then within five business days, TRAK shall exchange with the Company, and the Company shall accept, the smallest whole number of shares of Common Stock held by the TRAK Parties necessary to reduce the Common Percentage to 50% or less for shares of Series C Preferred having an aggregate Stated Value equal to that number of shares multiplied by the Conversion Price then in effect, and until that exchange is completed the excess shares shall be subject to the Voting Cap and shall not be voted or counted.
1.7.5 Calculations. Before each conversion, exercise or other issuance of Common Stock to a TRAK Party, the Company shall calculate the Common Percentage, using the number of outstanding shares of Common Stock reported by its transfer agent as of a date not more than two business days earlier, and shall deliver its calculation to TRAK. TRAK shall promptly provide any information the Company reasonably requests about Common Stock held by the TRAK Parties, and shall not acquire Common Stock from any other person without first confirming with the Company that the acquisition complies with this Section 1.7.
1.7.6 Void Issuances. Any issuance, transfer or acquisition of Common Stock in violation of this Section 1.7 shall be null and void ab initio to the extent of the excess. The Company shall not register or recognize, and shall instruct its transfer agent not to register or recognize, any Common Stock issued, transferred or acquired in violation of this Section 1.7, and no vote in respect of any such Common Stock shall be cast or counted.
1.7.7 Priority; Conforming Documents. To the extent any provision of Exhibit A (Credit Agreement), including any warrant issued under it, Exhibit B (Form of Series C Preferred Certificate of Designations), including the Certificate of Designations as filed, or Exhibit C (Form of Warrant), including the Warrant as issued, would permit or result in the Common Percentage exceeding 50% or the TRAK Parties casting or having counted more than 50% of the votes cast and counted on any matter, the terms of this Section 1.7 control, notwithstanding any conflict between this Section 1.7 and that provision and notwithstanding the introductory paragraph of Section 2 or any provision of an exhibit stating that it controls. This Section 1.7 also controls over any conflicting provision of any other Transaction Document. The Company and TRAK shall cause the Certificate of Designations, the Warrant, the Credit Agreement and each warrant issued under the Credit Agreement to contain provisions consistent with this Section 1.7. No amendment or waiver of this Section 1.7 shall be effective unless approved by a majority of the Company’s disinterested directors.
2. Terms of the Preferred Stock
The Company will file with the Delaware Secretary of State a Certificate of Designations for the Series C Preferred in the form of Exhibit B (the “Certificate of Designations”). The Certificate of Designations will be as set forth below. Subject to Section 1.7, to the extent of a conflict between the terms set forth below and the terms set forth in the Certificate of Designations, the terms of such Certificate of Designations shall control:
2.1* Stated Value*. The Stated Value for each share of Series C Preferred shall equal $1,000 per share (the “Stated Value”).
2.2* Conversion*. Each share of Series C Preferred shall be convertible at any time at the holder’s election and option into fully paid and nonassessable shares of Common Stock (“Conversion Shares”) calculated by dividing the Stated Value by $0.38 per share (the “Conversion Price”), with the number of Conversion Shares issuable on any conversion equal to the aggregate Stated Value of all shares of Series C Preferred being converted divided by the Conversion Price, and any fractional share of Common Stock resulting from that aggregate calculation rounded up to the next whole share, as provided in the Certificate of Designations. The Conversion Price shall adjust equitably for stock splits, stock dividends, combinations, reclassifications and similar events.
2.3* Ownership Cap on Conversion*. Notwithstanding anything to the contrary herein, no holder of Series C Preferred shall be entitled to convert any shares of Series C Preferred into Common Stock to the extent that, immediately after giving effect to such conversion, such holder (together with its affiliates and any other persons whose beneficial ownership would be aggregated with such holder’s for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (“Exchange Act”)) would cause the Common Percentage to exceed 50%. Any purported conversion in violation of this provision shall be null and void ab initio to the extent of such excess, and the shares of Series C Preferred subject to such excess shall remain outstanding and convertible in accordance with, and subject to the limitations of, this Section 2.3. This Section 2.3 shall not apply to any conversion on or after the Sunset Date (as defined in Section 1.7).
2.4* Voting*. The Series C Preferred shall vote together with the Common Stock as a single class on all matters. Each share of Series C Preferred is entitled to a number of votes equal to the number of whole shares of Common Stock into which it is then convertible (determined by dividing its Stated Value by the Conversion Price then in effect), and each share of Common Stock has one vote; provided, however, notwithstanding anything to the contrary herein, on any matter on which holders of Series C Preferred are entitled to vote together with holders of Common Stock as a single class, no holder of Series C Preferred (together with its affiliates and any other persons whose beneficial ownership would be aggregated with such holder’s for purposes of Section 13(d) of the Exchange Act) shall be entitled to cast votes, whether in respect of Preferred Stock, Common Stock or any other voting securities, in excess of 50% of the sum of (x) the votes cast and counted on such matter by such holder and such persons and (y) the total votes entitled to be cast on such matter by all other holders of voting securities, so that such holder and such persons may in no event cast more than 50% of the votes that may be cast and counted on such matter (the “Voting Cap”). Any votes that would otherwise be attributable to such holder in excess of the Voting Cap (the “Excess Votes”) shall not be voted or counted for any purpose, including determining a quorum and determining whether the requisite vote has been obtained. The Voting Cap applies equally to any action by written consent. The Voting Cap shall not apply on or after the Sunset Date. The Voting Cap shall not limit the right of holders of Series C Preferred to vote as a separate class on any matter for which such a class vote is required by law or by the Certificate of Designations. The votes per share of Series C Preferred Stock adjust equitably for stock splits, combinations, reclassifications and similar events.
2.5* Consent Rights*. The Company may not do any of the following without the consent of the holders of a majority of the outstanding Series C Preferred, voting together as a separate class: (a) amend the Certificate of Designations in a way that adversely affects the Series C Preferred; (b) increase the authorized number of shares of Series C Preferred; (c) authorize or issue any stock ranking senior to or on par with the Series C Preferred on liquidation, other than Series C Preferred issued under this Agreement or the Credit Agreement; (d) incur, assume or guarantee any indebtedness for borrowed money, other than indebtedness under the Credit Agreement (including under any Supported Facility or Sourced Financing, each as defined in the Credit Agreement) and the Existing TRAK Obligations; or (e) agree to do any of these things.
2.6* Dividends.* Dividends shall be paid at an annual rate of 8% per year on the Stated Value and are payable quarterly on March 31, June 30, September 30 and December 31, beginning with the first such date after issuance. The Company may pay each dividend in cash, in additional shares of Series C Preferred, or a combination thereof, at TRAK’s election; provided, however, in the event TRAK elects to receive additional shares of Series C Preferred in consideration for the payment of any dividend, dividends shall be paid at an annual rate of 10% per year. By way of illustration only, the initial quarterly dividend payable to TRAK shall equal $147,200 per quarter if paid in cash, or $184,000 if paid in additional shares of Series C Preferred, which amounts are calculated based on an initial Stated Value of Series C Preferred issued to TRAK of $7,360,000 (7,360 shares after rounding under Section 1.4) assuming Outstanding Indebtedness of $4,000,000.
2.7* Liquidation.* On any liquidation, dissolution or winding up of the Company, each share of Series C Preferred shall be entitled to receive, before any payment to the holders of Common Stock or any other junior stock, the Stated Value plus all accrued and unpaid dividends. The Series C Preferred shall rank senior to all other present and future classes and series of the Company’s equity securities.
2.8* Reservation of Common Stock. *Until the amendment described in Section 8.5 becomes effective, the Company will reserve for conversion of the Series C Preferred and exercise of the Warrant all of its authorized but unissued Common Stock that is not reserved for other outstanding securities disclosed in the SEC Reports. Thereafter, the Company will at all times reserve enough authorized but unissued Common Stock to permit conversion of all outstanding Series C Preferred, including shares issued as dividends or for Future Obligations, shares issued under the Credit Agreement, and Anti-Dilution Shares, and to permit exercise in full of the Warrant and of all warrants issued under the Credit Agreement.
3. Warrants. As additional consideration for the Exchanges, the Company shall issue to TRAK or its designee a warrant (the “Warrant”) to purchase a number of shares of Common Stock equal to fifty percent (50%) of the aggregate number of shares of Common Stock issuable upon conversion of all shares of Series C Preferred issued pursuant to Sections 1.1 and 1.2 of this Agreement at the Closing (the “Initial Warrant Shares”), rounded up to the next whole share. For purposes of determining the Initial Warrant Shares:
3.1 The number of shares of Series C Preferred issued pursuant to Section 1.1 shall equal the Outstanding Indebtedness as of the Closing Date, including all accrued and unpaid interest, divided by the $1,000 Stated Value, rounded up to the next whole share.
3.2 The number of shares of Series C Preferred issued pursuant to Section 1.2 shall equal $3,359,605 divided by the $1,000 Stated Value, rounded up to the next whole share.
3.3 The aggregate number of Conversion Shares shall equal the combined Stated Value of all Series C Preferred issued under Sections 1.1 and 1.2 divided by the Conversion Price of $0.38 per share, subject to adjustment as provided in the Certificate of Designations, with any fractional share of Common Stock rounded up to the next whole share. The calculation shall be performed on an aggregate basis without separately rounding the Common Stock attributable to each individual share of Series C Preferred.
3.4 The Initial Warrant Shares shall equal fifty percent (50%) of the aggregate Conversion Shares calculated under Section 3.3, rounded up to the next whole share.
3.5 The Company and TRAK shall execute a closing capitalization schedule setting forth the final Outstanding Indebtedness, the number of Series C Preferred shares issued under each Exchange, the aggregate Stated Value of such Series C Preferred, the aggregate Conversion Shares and the Initial Warrant Shares. Such schedule shall be incorporated into this Agreement as Appendix I and shall establish the initial number of Warrant Shares specified in the Warrant.
3.6 The Warrant shall have an exercise price of $0.38 per share, shall be substantially in the form of Exhibit C attached hereto, shall not be exercisable before January 31, 2028, shall have a four (4) year exercise term commencing on January 31, 2028, and shall expire, if not previously exercised, on January 31, 2032. The Warrant shall not be exercisable to the extent its exercise would cause the Common Percentage to exceed 50%, as provided in Section 1.7, and Exhibit C shall so provide. The limitation in the preceding sentence shall not apply to any exercise on or after the Sunset Date.
3.7 The Initial Warrant Shares shall remain subject to adjustment as provided in the Warrant.
4. [Reserved]
5. Elimination of Series B Preferred. The Company represents that no shares of its Series B Convertible Preferred Stock, par value $0.01 per share (“Series B Preferred”), are issued and outstanding. Promptly following the Closing, the Company will (i) cause the Board to adopt resolutions under Section 151(g) of the Delaware General Corporation Law stating that no shares of Series B Preferred are outstanding and that none will be issued under its certificate of designations; and (ii) file with the Delaware Secretary of State a certificate of elimination setting out those resolutions (the “Certificate of Elimination”), effective immediately upon filing. When the Certificate of Elimination becomes effective, everything in the Series B Preferred certificate of designations is removed from the Company’s certificate of incorporation, and the shares previously designated as Series B Preferred return to the status of authorized but unissued preferred stock, undesignated as to series.
6. Closing
6.1 Time. The Exchanges will close (the “Closing”) remotely by electronic exchange of documents on November 13, 2026, or another date the Company and TRAK agree (the “Closing Date”).
6.2 Company Deliveries. At the Closing, the Company will deliver to TRAK: (a) evidence that the Certificate of Designations and the Certificate of Elimination have been filed and are effective; (b) book-entry statements for the Series C Preferred issued under Section 1; and (c) Board resolutions, adopted by the vote required under Section 3.12 of the Company’s By-Laws and by a majority of the Company’s disinterested directors, approving this Agreement.
6.3 TRAK Deliveries. At the Closing, TRAK and PCG will deliver to the Company: (a) the original Note, marked cancelled; and (b) the Existing Shares, by book-entry transfer or with executed stock powers.
6.4 Conditions. Each party’s obligation to close depends on (a) the other parties’ deliveries under this Section 6 and (b) the other parties’ representations in Section 7 being true at the Closing. TRAK’s obligation also depends on the Certificate of Elimination being effective.
6.5 Termination. If the Closing has not occurred by November 13, 2026, the Company or TRAK may end this Agreement by written notice, unless the party giving notice caused the delay. Section 10 survives any termination of this Agreement as provided in Section 10.8.
7. Representations and Warranties
7.1 By the Company. The Company and, as to itself, SPM represent and warrant to TRAK as of the date of this Agreement and the Closing Date that:
7.1.1 Organization. The Company and SPM are Delaware and Nevada corporations, respectively, in good standing.
7.1.2 Authority. Each of the Company and SPM has the corporate power and authority to enter into and perform this Agreement. The Board has approved this Agreement, the Certificate of Designations, the Certificate of Elimination and all issuances of Series C Preferred (including as dividends or for Future Obligations, under the Credit Agreement, and as Anti-Dilution Shares) and of Common Stock on conversion of the Series C Preferred, and the issuance of the Warrant and of the warrants issuable under the Credit Agreement and of Common Stock on their exercise, by the vote required under Section 3.12 of the Company’s By-Laws (at least 70% of the directors then in office, including a majority of the Super Independent Directors, as defined in the By-Laws) and by a majority of the Company’s disinterested directors. No approval of the Company’s stockholders is required, other than the approval of the amendment to the Company’s certificate of incorporation described in Section 8.5. This Agreement is a binding obligation of each, enforceable in accordance with its terms.
7.1.3 Capitalization. The Company’s authorized stock consists of 47,000,000 shares of Common Stock and 3,000,000 shares of preferred stock, par value $0.01 per share. As of August 6, 2026, 28,398,560 shares of Common Stock were outstanding, and no shares of preferred stock are outstanding. Except as disclosed in the reports filed with the Securities and Exchange Commission (“SEC”) (“SEC Reports”), there are no outstanding options, warrants, or other rights to acquire the Company’s Common Stock.
7.1.4 Valid Issuance. The Series C Preferred, and the Common Stock issuable on its conversion, when issued under this Agreement and the Certificate of Designations (and, to the extent required, after the amendment described in Section 8.5 becomes effective), will be duly authorized, validly issued, fully paid and nonassessable, free of liens and preemptive rights. As of the Closing, the Company has reserved for issuance on conversion of the Series C Preferred and exercise of the Warrant all of its authorized but unissued shares of Common Stock that are not reserved for other outstanding securities disclosed in the SEC Reports. The Company acknowledges that its authorized Common Stock is not sufficient to permit the conversion in full of the Series C Preferred and the exercise in full of the Warrant, and that it will increase its authorized Common Stock as required by Section 8.5.
7.1.5 No Conflicts. Signing and performing this Agreement will not violate the Company’s certificate of incorporation or bylaws, any law or court order applicable to it, or any material agreement to which it is a party. No consent or filing is required other than the filings described in this Agreement and a Current Report on Form 8-K; provided, however, the parties acknowledge that the consent of North Mill Capital, LLC, d/b/a SLR Business Credit ("NM") is required for SPAR to incur additional indebtedness of $1.5 million, which SPAR will use its best interest to obtain. Notwithstanding the foregoing, the consent of NM shall not delay or effect Closing, or the advancement of funds under the Credit Agreement.
7.1.6 SEC Reports. Since January 1, 2025, the Company has timely filed all SEC Reports required under the Exchange Act. Other than voluntary restatements, which restatements have been filed with the SEC, the SEC Reports did not contain any untrue statement of a material fact or omit any material fact needed to make them not misleading, and the financial statements in them fairly present the Company’s financial condition in all material respects.
7.1.7 No Material Adverse Change. Since September 30, 2026, there has been no material adverse change in the Company’s business, financial condition or results of operations, except as disclosed in the SEC Reports.
7.1.8 Litigation. Other than as disclosed in SEC Reports, there is no pending or, to the Company’s knowledge, threatened lawsuit or proceeding that challenges the transactions in this Agreement or would reasonably be expected to have a material adverse effect on the Company.
7.1.9 Anti-Takeover Provisions. The Board has taken all action needed so that Section 203 of the Delaware General Corporation Law and any other anti-takeover provision in the Company’s certificate of incorporation, bylaws or any rights plan do not apply to TRAK, its affiliates, or the transactions in this Agreement, including TRAK’s acquisition of the Series C Preferred and the Common Stock issuable on its conversion. Without limiting the foregoing, the Board approved, before TRAK first became an “interested stockholder” (as defined in Section 203), the transaction that resulted in TRAK becoming one, or Section 203 does not apply to the Company under Section 203(b)(4).
7.1.10 No Brokers. No broker or finder is entitled to a fee from the Company in connection with the transactions contemplated by this Agreement; provided, however, SPAR may owe Lincoln International, LLC an amount up to $200,000 in connection with the transactions contemplated by this Agreement.
7.2 By TRAK and PCG. Each of TRAK and PCG represents and warrants to the Company, as to itself, as of the date of this Agreement and the Closing Date that:
7.2.1 Organization and Authority. It is a corporation in good standing under the laws of its state of incorporation, has the power and authority to enter into and perform this Agreement, and this Agreement is its binding obligation, enforceable in accordance with its terms.
7.2.2 Title. It owns the Note or the Existing Shares it is delivering, free of any lien or claim, and has not assigned any interest in them. The Outstanding Indebtedness that TRAK confirms under Section 1.1 will be accurate.
7.2.3 No Conflicts. Signing and performing this Agreement will not violate its organizational documents, any law applicable to it, or any material agreement to which it is a party.
7.2.4 Investor Status. It is an “accredited investor” as defined in Rule 501(a) under the Securities Act of 1933, as amended (the “Securities Act”), has had access to the information about the Company it considers necessary to make its decision, and is acquiring the Preferred Stock for its own account for investment and not with a view to distribution.
7.2.5 No Brokers. No broker or finder is entitled to a fee from it in connection with the transactions.
7.3 No Other Representations. No party makes any representation or warranty other than those in this Section 7.
8. Section 3(a)(9) Exchange and Securities Matters
8.1 Section 3(a)(9). The Exchanges and any later conversion of the Series C Preferred into Common Stock, are structured as exchanges by the Company with its existing security holders exclusively, under Section 3(a)(9) of the Securities Act. TRAK and PCG are giving no consideration other than the Note, the Existing Shares or the Series C Preferred being exchanged. No commission or other remuneration has been or will be paid, directly or indirectly, for soliciting any exchange. If Section 3(a)(9) is unavailable for any exchange of Future Obligations, that exchange is intended to be exempt under Section 4(a)(2) of the Securities Act.
8.2 Holding Period. For purposes of Rule 144 under the Securities Act, the parties intend that the holding period of the Series C Preferred, and of the Common Stock issued on its conversion, includes the holding period of the Note or Existing Shares exchanged for it. The Company will not take any contrary position unless required by law.
8.3 Legends. The Series C Preferred and any Common Stock issued on conversion will carry a customary Securities Act restrictive legend. The Company will remove the legend promptly when the shares may be sold under Rule 144 or an effective registration statement, and will provide any opinion of counsel or instruction its transfer agent requires.
8.4 Current Report on Form 8-K. The Company will file a Current Report on Form 8-K describing the transactions within four business days after the date of this Agreement and after the Closing, as required.
8.5 Increase in Authorized Common Stock. The Company shall, on or before January 31, 2028, take all corporate action necessary to amend its certificate of incorporation to increase the number of authorized shares of Common Stock to a number sufficient to permit (a) the conversion in full of all outstanding shares of Series C Preferred, including shares issued as dividends, for Future Obligations, under the Credit Agreement and as Anti-Dilution Shares, and (b) the exercise in full of the Warrant and of all warrants issued under the Credit Agreement, in each case without regard to the beneficial ownership limitation in Section 2.3, the Voting Cap or any other limitation on conversion or exercise, and shall reserve those shares for such purposes. That action shall include (i) causing the Board to approve the amendment, declare it advisable and recommend that the Company’s stockholders approve it; (ii) calling and holding a meeting of stockholders (or obtaining stockholder action by written consent, if permitted) for that purpose, and soliciting proxies in favor of the amendment to the same extent as for the Board’s other proposals; and (iii) filing the amendment with the Secretary of State of the State of Delaware promptly after it is approved. If, at any time after the amendment becomes effective, the authorized and unreserved Common Stock is insufficient for the purposes described in this Section 8.5, the Company shall promptly take the same actions to increase it. Section 9.3 applies to this Section 8.5, and the parties agree that money damages would not be an adequate remedy for its breach.
9. Dispute Resolution
9.1 Negotiation. If a dispute arises under this Agreement, senior executives of the Company and TRAK will meet within 15 days after either gives written notice of the dispute and try in good faith to resolve it.
9.2 Arbitration. Any dispute not resolved within 30 days after that notice will be resolved by confidential, binding arbitration administered by the American Arbitration Association under its Commercial Arbitration Rules, before a single arbitrator, seated in Wilmington, Delaware. The arbitrator’s award is final and may be entered in any court with jurisdiction. Each party bears its own costs, and the parties share the arbitration fees equally, unless the arbitrator decides otherwise.
9.3 Court Relief. Despite Section 9.2, any party may seek specific performance, an injunction or other interim relief in the Delaware Court of Chancery (or, if it lacks jurisdiction, a state or federal court in Delaware), including to enforce Sections 1 and 3. The parties agree that money damages would not be an adequate remedy for a breach of those Sections. EACH PARTY WAIVES ANY RIGHT TO A JURY TRIAL IN ANY SUCH COURT PROCEEDING.
10. Indemnification
10.1 Indemnification by TRAK. Subject to the other provisions of this Section 10, TRAK shall indemnify and hold harmless the Company, each of its subsidiaries and other affiliates (excluding TRAK, PCG and their respective subsidiaries), each person who is or was a director or officer of the Company or any of its subsidiaries, and each such person’s heirs and legal representatives (each, a “Company Indemnified Party”), from and against all losses, liabilities, judgments, fines, amounts paid in settlement, and costs and expenses (including reasonable fees and expenses of counsel and experts) (collectively, “Losses”) that any Company Indemnified Party incurs in connection with any threatened, pending or completed claim, action, suit or proceeding, whether civil, administrative or investigative, and whether brought directly, derivatively or on behalf of a class (each, a “Fiduciary Claim”), to the extent it alleges that any present or former director or officer of the Company or any of its subsidiaries breached any fiduciary duty (including the duties of care, loyalty, good faith and disclosure), or that any person aided and abetted such a breach, in connection with the evaluation, negotiation, approval, execution or delivery of this Agreement or the consummation of the Exchanges.
10.2 Excess Indemnity; Order of Payment. TRAK’s obligations under this Section 10 are secondary to, and in excess of, (a) all directors’ and officers’ liability insurance maintained by the Company or any of its subsidiaries (the “D&O Insurance”), and (b) the Company’s obligations to indemnify and advance expenses to its directors and officers under its certificate of incorporation (the “Charter Indemnification”). Accordingly, TRAK shall be obligated to pay a Loss only to the extent it exceeds the sum of all amounts paid for that Loss under the D&O Insurance and under the Charter Indemnification, and only after (i) the applicable limits of the D&O Insurance have been exhausted by payment, or each applicable insurer has denied coverage for that Loss in writing, and (ii) the Company has paid all amounts that it is required, and permitted by applicable law, to pay for that Loss under the Charter Indemnification. Losses of the Company do not include any amount the Company pays under the Charter Indemnification or any retention or deductible under the D&O Insurance.
10.3 Primary Sources. The Company shall (a) maintain D&O Insurance for at least six years after the date of this Agreement with coverage and limits no less favorable to the insureds than the D&O Insurance in effect on the date of this Agreement; (b) not amend its certificate of incorporation in any way that reduces the Charter Indemnification as it applies to any Fiduciary Claim; and (c) together with each Company Indemnified Party seeking indemnification, use commercially reasonable efforts to recover each Loss under the D&O Insurance and the Charter Indemnification before seeking payment from TRAK.
10.4 Advancement. Once the conditions in clauses (i) and (ii) of Section 10.2 have been satisfied for a Fiduciary Claim, TRAK shall advance the reasonable defense costs of each Company Indemnified Party who is or was a director or officer for that Fiduciary Claim within 30 days after receiving reasonably detailed invoices, subject to that person’s written undertaking to repay the amounts advanced if it is finally determined that the person is not entitled to indemnification under this Section 10.
10.5 Exclusions. TRAK has no obligation under this Section 10 for any Loss (a) to the extent a court of competent jurisdiction finally determines that the Loss resulted from the Company Indemnified Party’s fraud, intentional misconduct, or receipt of a personal financial benefit to which it was not legally entitled; (b) arising from a Fiduciary Claim brought by TRAK, PCG or any of their affiliates; or (c) to the extent the Company Indemnified Party has actually received payment for that Loss from any other source.
10.6 Procedures. A Company Indemnified Party seeking indemnification shall give TRAK prompt written notice of the Fiduciary Claim, but a delay in giving notice relieves TRAK of its obligations only to the extent TRAK is materially prejudiced by the delay. The Company shall keep TRAK reasonably informed of the status of each Fiduciary Claim, and TRAK may participate in its defense at its own expense through counsel of its choice. No Company Indemnified Party may settle a Fiduciary Claim, or consent to the entry of any judgment, for which TRAK may be required to pay any amount without TRAK’s prior written consent, which TRAK will not unreasonably withhold, condition or delay.
10.7 Subrogation; Excess Position. On making any payment under this Section 10, TRAK will be subrogated to the rights of the Company Indemnified Party to recover that amount under the D&O Insurance and the Charter Indemnification, and each Company Indemnified Party shall sign the documents reasonably required to secure those rights. Neither the Company nor any Company Indemnified Party shall take the position, with any insurer or otherwise, that TRAK’s obligations under this Section 10 are primary to the D&O Insurance or the Charter Indemnification, or seek contribution or reimbursement from TRAK for any amount paid under either of them.
10.8 Third-Party Beneficiaries; Survival; Amendment. Each Company Indemnified Party that is not a party to this Agreement is an express third-party beneficiary of this Section 10 and may enforce it directly. This Section 10 survives the Closing and any termination of this Agreement until 60 days after the expiration of the statute of limitations applicable to Fiduciary Claims, and thereafter as to any Fiduciary Claim asserted before then until it is finally resolved. Despite Section 11.1, this Section 10 may not be amended or waived in a way that adversely affects any Company Indemnified Party without that person’s written consent.
11. General
11.1 Entire Agreement. This Agreement, with its exhibits, is the parties’ entire agreement on its subject and replaces the term sheet and all prior discussions. It may be amended or waived only in a writing signed by the Company and TRAK.
11.2 Further Actions. Each party will sign the documents and take the further actions reasonably needed to carry out this Agreement.
11.3 Expenses. Each party pays its own expenses.
11.4 Governing Law. Delaware law governs this Agreement.
11.5 Notices. Notices must be in writing and are effective when delivered by hand, by email with confirmation of receipt, or by overnight courier to the addresses on the signature page.
11.6 Counterparts. This Agreement may be signed in counterparts and by electronic signature, each of which is an original.
11.7 Survival. The representations and warranties in Section 7 survive the Closing for 12 months. Each covenant survives until fully performed, and Section 8 survives as stated therein. Section 10 survives as stated therein.
11.8 Assignment. No party may assign this Agreement without the written consent of the Company and TRAK, except that TRAK may assign its rights to an affiliate that agrees in writing to be bound by this Agreement.
11.9 Tax Treatment. For income tax purposes, the Series C Preferred issued for the Note will be allocated first to the principal of the Note and then to accrued but unpaid interest. The parties intend each Exchange in Section 1 to qualify as a recapitalization under Section 368(a)(1)(E) of the Internal Revenue Code, to the extent permitted by law. Each party will file its tax returns consistently with this Section unless otherwise required by a final determination of a taxing authority, and each party is responsible for its own taxes arising from the transactions.
[Signature page follows]
The parties have signed this Agreement as of the date first written above.
| SPAR GROUP, INC. | REPOSITRAK, INC. |
| By: ____________________ | By: ____________________ |
| Name: William Linnane | Name: Randy Fields |
| Title: Chief Executive Officer | Title: Chief Executive Officer |
| Address/email: wlinnane@sparinc.com | Address/email: rfields@repositrak.com |
| SPAR MARKETING FORCE INC. | PC GROUP, INC. |
| By: ____________________ | By: ____________________ |
| Name: William Linnane | Name: Randy Fields |
| Title: Chief Executive Officer | Title: Chief Executive Officer |
Exhibits
| ● | Exhibit A - Revolving Credit Agreement | |
| ● | Exhibit B - Form of Series C Preferred Certificate of Designations | |
| ● | Exhibit C - Form of Warrant |